Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients
- PMID: 7676810
- DOI: 10.1007/BF00571510
Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients
Abstract
Interleukin-6 (IL-6) immunoreactivity has previously been shown in plaques in Alzheimer's disease (AD) and elevated IL-6 concentrations have been measured biochemically in brains of AD patients. In this study, we investigated the appearance of IL-6 immunoreactivity in AD plaques according to the stage of plaque formation. Using the Bielschowsky silver-staining method, we were able to differentiate between four types of plaques described earlier: diffuse, primitive, classic and compact. While diffuse plaques represent the early stage of plaque formation, primitive and classic plaques are thought to represent later stages of plaque development. We investigated serial sections of paraffin-embedded cortices of ten clinically diagnosed and histopathologically confirmed AD patients and ten patients with no clinical history of dementia. We found plaques in the brains of both nondemented and demented persons using the silver staining method or immunohistochemistry with antibodies against the amyloid precursor protein. In the group of clinically nondemented persons, diffuse plaques were the predominant plaque type, whereas primitive plaques formed the larger portion of lesions in the group of AD brains. IL-6 could not be detected in plaques of patients without dementia. Many IL-6-positive plaques were found in six of the AD brains and to a smaller extent in the other four AD cases. In the six cases with a large number of IL-6-positive plaques, IL-6 was found in a significantly higher ratio of diffuse plaques than expected from a random distribution of IL-6 in all plaque types.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Occurrence of interleukin-6 in cortical plaques of Alzheimer's disease patients may precede transformation of diffuse into neuritic plaques.Ann N Y Acad Sci. 1996 Jan 17;777:205-12. doi: 10.1111/j.1749-6632.1996.tb34420.x. Ann N Y Acad Sci. 1996. PMID: 8624085
-
The participation of interleukin-6, a stress-inducible cytokine, in the pathogenesis of Alzheimer's disease.Behav Brain Res. 1996 Jun;78(1):37-41. doi: 10.1016/0166-4328(95)00213-8. Behav Brain Res. 1996. PMID: 8793035
-
Inflammatory mechanisms in Alzheimer's disease.Eur Arch Psychiatry Clin Neurosci. 1996;246(3):124-8. doi: 10.1007/BF02189112. Eur Arch Psychiatry Clin Neurosci. 1996. PMID: 8739396 Review.
-
Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain.Am J Pathol. 1994 Feb;144(2):337-47. Am J Pathol. 1994. PMID: 8311117 Free PMC article.
-
Distribution of beta/A4 protein and amyloid precursor protein in hereditary cerebral hemorrhage with amyloidosis-Dutch type and Alzheimer's disease.Am J Pathol. 1993 May;142(5):1449-57. Am J Pathol. 1993. PMID: 7684195 Free PMC article. Review.
Cited by
-
The role of inflammatory processes in Alzheimer's disease.Inflammopharmacology. 2012 Jun;20(3):109-26. doi: 10.1007/s10787-012-0130-z. Epub 2012 Apr 26. Inflammopharmacology. 2012. PMID: 22535513 Review.
-
Long-term dietary supplementation of pomegranates, figs and dates alleviate neuroinflammation in a transgenic mouse model of Alzheimer's disease.PLoS One. 2015 Mar 25;10(3):e0120964. doi: 10.1371/journal.pone.0120964. eCollection 2015. PLoS One. 2015. PMID: 25807081 Free PMC article.
-
Inflammation as a central mechanism in Alzheimer's disease.Alzheimers Dement (N Y). 2018 Sep 6;4:575-590. doi: 10.1016/j.trci.2018.06.014. eCollection 2018. Alzheimers Dement (N Y). 2018. PMID: 30406177 Free PMC article. Review.
-
Irisin reduces amyloid-β by inducing the release of neprilysin from astrocytes following downregulation of ERK-STAT3 signaling.Neuron. 2023 Nov 15;111(22):3619-3633.e8. doi: 10.1016/j.neuron.2023.08.012. Epub 2023 Sep 8. Neuron. 2023. PMID: 37689059 Free PMC article.
-
TDO as a therapeutic target in brain diseases.Metab Brain Dis. 2016 Aug;31(4):737-47. doi: 10.1007/s11011-016-9824-z. Epub 2016 Apr 13. Metab Brain Dis. 2016. PMID: 27072164 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical